Share on StockTwits

Enanta Pharmaceuticals (NASDAQ:ENTA) Director Stephen Jr. Buckley acquired 1,000 shares of the stock on the open market in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average price of $38.95 per share, for a total transaction of $38,950.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $38,950. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Credit Suisse raised their price target on shares of Enanta Pharmaceuticals from $43.00 to $44.00 in a research note on Friday. They now have an “outperform” rating on the stock. Separately, analysts at FBR Capital Markets initiated coverage on shares of Enanta Pharmaceuticals in a research note on Thursday. They set an “outperform” rating and a $52.00 price target on the stock. Finally, analysts at Zacks upgraded shares of Enanta Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday. They now have a $47.10 price target on the stock. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Enanta Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $45.82.

Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 1.53% on Friday, hitting $39.79. The stock had a trading volume of 269,263 shares. Enanta Pharmaceuticals has a 52 week low of $18.21 and a 52 week high of $46.443. The stock has a 50-day moving average of $39.48 and a 200-day moving average of $38.43. The company has a market cap of $739.4 million and a P/E ratio of 21.10.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, August 11th. The company reported $2.61 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.67 by $0.94. The company had revenue of $42.10 million for the quarter, compared to the consensus estimate of $40.83 million. Enanta Pharmaceuticals’s revenue was up 2531.3% compared to the same quarter last year. On average, analysts predict that Enanta Pharmaceuticals will post $1.56 earnings per share for the current fiscal year.

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.